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and Denis S Loiselle1,2Abstract
Background: Diabetes is known to alter the energy metabolism of the heart. Thus, it may be expected to affect
the efficiency of contraction (i.e., the ratio of mechanical work output to metabolic energy input). The literature on
the subject is conflicting. The majority of studies have reported a reduction of myocardial efficiency of the diabetic
heart, yet a number of studies have returned a null effect. We propose that these discrepant findings can be
reconciled by examining the dependence of myocardial efficiency on afterload.
Methods: We performed experiments on streptozotocin (STZ)-induced diabetic rats (7-8 weeks post-induction),
subjecting their (isolated) hearts to a wide range of afterloads (40 mmHg to maximal, where aortic flow approached
zero). We measured work output and oxygen consumption, and their suitably scaled ratio (i.e., myocardial efficiency).
Results: We found that myocardial efficiency is a complex function of afterload: its value peaks in the mid-range and
decreases on either side. Diabetes reduced the maximal afterload to which the hearts could pump (105 mmHg
versus 150 mmHg). Thus, at high afterloads (for example, 90 mmHg), the efficiency of the STZ heart was lower than
that of the healthy heart (10.4% versus 14.5%) due to its decreased work output. Diabetes also reduced the afterload
at which peak efficiency occurred (optimal afterload: 63 mmHg versus 83 mmHg). Despite these negative effects,
the peak value of myocardial efficiency (14.7%) was unaffected by diabetes.
Conclusions: Diabetes reduces the ability of the heart to pump at high afterloads and, consequently, reduces the
afterload at which peak efficiency occurs. However, the peak efficiency of the isolated working rat heart remains
unaffected by STZ-induced diabetes.
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Efficiency-afterload relationBackground
Cardiac efficiency (calculated from the ratio of work to
oxygen consumption) has been used extensively as an
index of energetics of the myocardium. In many studies
of the energetics of the diabetic heart, the deterioration
of cardiac performance has been linked to a reduction of
cardiac efficiency [1-5]. But, some studies have reported
an unchanged value in diabetic animals [6-9]. We propose
that these conflicting findings are a consequence of* Correspondence: j.han@auckland.ac.nz
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stated.reporting only a single value of efficiency. As experimen-
tally shown using one-dimensional cardiac preparations,
such as papillary muscles [10-16] and trabeculae carneae
[17,18], cardiac efficiency is a complex function of after-
load (Figure 1). It has a peak value somewhere in the mid-
dle of the afterload range. Hence, reporting only a single
value of efficiency is somewhat incomplete, and could per-
haps mislead the author into reaching a faulty conclusion,
even to the extent of erring on the direction of the differ-
ence. We elaborate this point using Figure 1, where we
propose three cases.
We term the afterload at which the efficiency peaks
the ‘optimal afterload’, as distinct from ‘peak afterload’. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Figure 1 Schematic representations of three possible relations between myocardial efficiency and left-ventricular afterload. Myocardial
efficiency as a function of afterload proposed for the control heart (thin line) and for the diabetic heart (thick line). The diabetic heart could have
(A) a lower value of peak efficiency (which occurs at the optimal afterload as indicated by the broken line labelled ‘O’) but can pump to the
same peak afterload (the broken line labelled ‘P’), lower peak efficiency and lower peak afterload (B), or same peak efficiency but lower peak
afterload (C).
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the first case (Figure 1A), compared with the control
heart, the diabetic heart has a lower value of peak effi-
ciency, but the same optimal afterload and the same
peak afterload. Adoption of the same peak afterload is
based on experimental results showing no difference
in the left-ventricular systolic pressure [1,2,19,20]. But,
there exists evidence that the left-ventricular systolic
pressure is lower in the diabetic heart [4,9,21-25], which
leads us to consider two other cases, in which the dia-
betic heart has a lower peak afterload and a lower opti-
mal afterload, but its peak efficiency can be either lower
than (the second case; Figure 1B), or the same as (the
third case; Figure 1C), that of the control heart. In all
three cases, one would reach the conclusion that the dia-
betic heart has a lower cardiac efficiency if the experiment
had been performed at a high afterload. But, if measure-
ments had been made at or around the optimal afterload
(the third case), then one would find that the diabetic heart
has the same efficiency as the control heart.
The objectives of our study were hence threefold: (i) to
determine the effect of diabetes on cardiac mechano-
energetics, (ii) to extend the single value of cardiac effi-
ciency of the diabetic heart, as reported in the literature, to
its expression as a function of afterload, and (iii) to recon-
cile the conflicting findings showing either a decrease, or
no change, of the cardiac efficiency of the diabetic heart.
We conducted experiments using streptozotocin-induced
diabetic hearts isolated from rats. Each heart, under work-
ing mode, was challenged to a series of afterloads from
40 mmHg to its maximal capacity.
Methods
Animal preparation
Male Sprague–Dawley rats (6-7 weeks old, 250-300 g)
were made diabetic by a single tail vein injection of
streptozotocin (STZ; 55 mg/kg). Control (SHAM) rats
were given an intravenous injection of an equivalentvolume of saline. Rats in each group were housed in
pairs in a cage at room temperature (20-22°C) on a
12-hr light/dark cycle with ad libitum access to food
(standard rat chow) and tap water. Blood glucose level
was measured daily for the first week and once per week
thereafter for 7-8 weeks. Induction of diabetes in the
STZ-treated rats was confirmed by blood glucose >20 mM.
Experiments were conducted in accordance with protocols
approved by The University of Auckland Animal Ethics
Committee.
Measurement of blood pressure
From each group, 4 rats were subjected to measurement
of blood pressure in vivo. During the surgical period,
they were continuously anesthetised using inhaled iso-
flurane (2.5%). Under sterile conditions, each rat was surgi-
cally implanted with a blood pressure telemeter (Model
TRM53P, Telemetry Research, Auckland, NZ) with a solid-
state pressure sensor at the tip of the catheter. The
abdominal aorta was cannulated 1–2 cm rostral to the
iliac bifurcation and the sensor tip of the telemeter ad-
vanced proximally 1–2 cm. Pain relief/analgesia (Temgesic,
20 mg/kg) and antibiotic (Baytril 2.5% solution, 0.8 mL/kg)
were administered at the time of the surgery. The rats were
monitored closely and analgesia given daily for up to 3 days
after the surgery.
The arterial pressure signal was sampled at 500 Hz
using an analogue–digital data acquisition card (PCI
6024E, National Instruments, TX, USA) and continuously
displayed by a data acquisition programme (Universal
Acquisition 11, University of Auckland, Auckland, NZ).
Heart rate, and systolic and diastolic blood pressures were
derived from the arterial pressure waveform. For the
calculation of the overall average level of mean arterial
blood pressure, the sampled signals were averaged every
2 s. All subsequent data collection and analyses were per-
formed using the same data analysis programme. Rats
were monitored for at least 12 days to ensure they were
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ing the mean values for the last 5 days of the recordings
(7-8 weeks post-injection).
Heart preparation
At 7-8 weeks post-injection, a rat was deeply anaesthe-
tised with isoflurane (5% in O2), injected with heparin
(1000 IU/kg), and body mass measured. Following cer-
vical dislocation, the heart and lungs were excised and
plunged into chilled Tyrode solution. The aorta was imme-
diately cannulated for Langendorff perfusion (afterload
70 mmHg) with Tyrode solution at room temperature. The
lungs were then separated from the heart. The Tyrode so-
lution had compositions of (in mM): 130 NaCl, 6 KCl,
1 MgCl2, 0.5 NaH2PO4, 1.5 CaCl2, 10 Hepes, 10 glucose,
its pH adjusted to 7.4 using Tris and was vigorously bub-
bled with 100% O2. Glucose at a concentration of 10 mM
has been shown to be sufficient to optimise the mechanical
performance of the diabetic heart [26].
The venae cavae (right superior, left superior and
inferior) were ligated, as were three of the pulmonary
veins, leaving one for cannulation. The pulmonary artery
was also cannulated. Oxygen sensors (FOXY-R-8CM,
NeoFox@ Phase Measurement System, Ocean Optics Inc.,
FL, USA), with their associated temperature probes, were
inserted into the aortic cannula (to reside just above the
coronary ostia) and the arterial cannula, for measuring
the coronary arterial partial pressure of O2 (PO2) and the
coronary venous PO2, respectively. Flow probes, con-
nected to flow meters (T206 and T106, Transonic System
Inc., NY, USA), measured the rate of aortic outflow and
the rate of coronary outflow. The fully-instrumented heart
was enveloped by a water-jacketed glass chamber, and the
temperature elevated to 32°C. Finally, the intrinsic heart
rate was measured and a unipolar stimulus electrode
(Coaxial Stimulation Electrode, Harvard Apparatus, MA,
USA) was placed on the surface of the right atrium and
the heart was paced at 4 Hz (which, in all cases, was
above the intrinsic rate of beating).
Experimental protocol
Upon attaining steady-state of the rate of coronary flow
under Langendorff mode, perfusion was then switched
to working-heart mode (preload 20 mmHg and after-
load 70 mmHg). Preload and afterload (measured using in-
line physiological pressure transducers: SP 844 Transducer,
MEMSCAP Inc., NC, USA) were varied by changing the
height, above the mid-level of the heart, of the preload
chamber and the aortic outflow tubing, respectively. The
afterload for the RV was fixed at 10 mmHg. When each of
the measured variables had reached steady states, the after-
load was altered to a new value. Afterloads were presented
in random order within the range between 40 mmHg and
maximal (at which point aortic flow was near zero). Whenthe series of afterload interventions was completed, perfu-
sion was switched back to Langendorff mode (afterload
70 mmHg) to measure the basal rate of VO2 of the heart
(cardiac arrest induced by high KCl, 26 mM). Data
were continuously acquired and recorded using PowerLab
LabChart Pro. software (ADInstruments, Dunedin, NZ). In
total, 16 STZ-diabetic hearts and 17 SHAM hearts were
used in this study.
Trans-epicardial exchange of oxygen
Myocardial VO2 was corrected for the trans-epicardial
exchange of oxygen with the surrounding air in the glass
chamber housing the heart. During the course of an
experiment, the gaseous content in the glass chamber
was flushed with 21% O2. Upon completion of the after-
load series, the gaseous content in the glass chamber
was changed to 100% O2 and the afterload was set at
50 mmHg. This resulted in an increase in the measured
venous PO2 and, consequently, a decrease in the calcu-
lated steady-state rate of myocardial oxygen consump-
tion, reflecting a diminution in the loss of oxygen from
the coronary circulation across the epicardial surface.
The true value of myocardial VO2 was calculated by
making use of the values measured in the presence of
21% and 100% O2 in the heart chamber, as previously
described [27,28].
Calculations
The rate of performance of work ( _W ) was given by
the product of the afterload and the total (coronary plus
aortic) flow. The rate of oxygen consumption was given by
the product of the arterio-venous difference in PO2 and
the coronary flow, assuming an oxygen solubility of
0.0249 mL atm-1 mL-1 at 32°C [27], and the enthalpy
equivalent of O2 to be 20 J mL
-1 [29]. ‘Total efficiency’
(ɛTotal) was defined as the ratio of the rate of performing
work to the rate of total enthalpy production Δ _HTotal
 
.
‘Mechanical efficiency’ (ɛMech) was calculated from total ef-
ficiency by subtracting the rate of enthalpy production in












At the end of each experiment, the ventricles were
opened to measure the thickness of the septum and the
LV and RV walls. The heart was then blotted and its wet
mass measured. Work and VO2 were expressed per beat
by dividing by stimulus frequency (4 Hz). The work,
Table 1 General features of SHAM and STZ rats
Parameter SHAM STZ
Body mass (g) 538 ± 15 375 ± 13*
Tibial length (mm) 45.4 ± 0.6 42.2 ± 0.6*
Lung mass (g) 2.05 ± 0.09 1.89 ± 0.06
Lung mass/body mass (%) 0.38 ± 0.02 0.52 ± 0.03*
Heart mass (g) 1.49 ± 0.05 1.16 ± 0.04*
Heart mass/body mass (%) 0.28 ± 0.01 0.31 ± 0.01*
RV wall thickness (mm) 1.33 ± 0.04 1.16 ± 0.06*
LV wall thickness (mm) 3.80 ± 0.09 3.74 ± 0.09
Septal wall thickness (mm) 3.18 ± 0.07 3.14 ± 0.11
RV thickness/heart mass (mm g-1) 0.91 ± 0.03 1.02 ± 0.06
LV thickness/heart mass (mm g-1) 2.60 ± 0.10 3.26 ± 0.12*
Septal thickness/heart mass (mm g-1) 2.16 ± 0.07 2.74 ± 0.13*
Blood glucose (mM) 6.8 ± 0.1 29.6 ± 0.5*
Systolic blood pressure (mmHg) 129 ± 2.8 125 ± 2.9
Diastolic blood pressure (mmHg) 84 ± 2.2 82 ± 2.2
Mean arterial blood pressure (mmHg) 103 ± 2.3 102 ± 2.6
Heart rate in vivo (beats min-1) 346 ± 16 302 ± 5*
Heart rate in vitro (beats min-1) 175 ± 7 156 ± 5*
Values are means ± SE. In all cases, n = 17 for SHAM and n = 16 for STZ, except
for blood pressure and heart rate in vivo, both n = 4.
Asterisks indicate statistically significant differences in mean values between
SHAM and STZ: *P < 0.05.
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of VO2 were normalised to heart wet mass and thus
expressed in units of J kg-1, mL min-1 kg-1 or W kg-1,
where appropriate. Whereas the tissues of both ventri-
cles are perfused (and actively contracting), the RV per-
forms work against a negligible afterload (10 mmHg). As
a result, by normalising oxygen consumption to the
mass of the entire heart, we slightly underestimate the
work (and, hence, efficiency) of the whole-heart but have
no reason to expect any difference between hearts of
STZ and SHAM animals.
Data fitting
Aortic flow, coronary flow and VO2, were plotted against
afterload and the data fitted using 3rd-order polynomials.
Work and total ɛTotal were likewise plotted against after-
load and fitted using 3rd-order polynomials but with in-
tercepts set to zero (since work is zero at zero afterload).
The regression lines within a group (16 for the STZ
group and 17 for the SHAM group) were averaged using
the Nonlinear Mixed Model (PROC NLMIXED) of the
SAS software package. Regression coefficients were as-
sumed to have arisen from a multivariate normal prob-
ability distribution [30].
Statistical analyses
Parameters of interest, estimated from each regression
line defining the dependence of the measured variables
on afterload (i.e., peak value, optimal afterload and peak
afterload), were averaged and expressed as means ±
standard error (SE). The data arising from all of the
dependent variables were analysed using Hotelling’s T2, the
two-group (STZ versus SHAM) equivalent of MANOVA
(Multivariate Analysis of Variance), prior to performing
multiple ANOVAs on individual variables. Means were ad-
judged to be different if P < 0.05. Note that, for a 5% risk of
a Type I Error, and with n = 16 or 17 observations per
group, the statistical power to detect a separation of means
of at least one standard deviation is 80% [31].
Results
Morphometric characteristics of the rats
As displayed in Table 1, compared with the control rats
(SHAM), the streptozotocin (STZ)-induced diabetic rats
had elevated blood glucose. They had, on average, smaller
body mass, shorter tibial length and smaller hearts. Their
average heart wall thickness did not differ for either the left
ventricle (LV) or the septum, but was higher in the right
ventricle (RV) of the STZ group. When the wall thickness
was expressed as a fraction of heart wet mass, the differ-
ence in mean relative RV thickness was no longer statisti-
cally significant, but the mean relative thickness of both
the septum and LV were greater. No statistical difference
was detected for the average lung wet mass, but whenexpressed as a percentage of body mass, the STZ rats had
a greater mean relative lung mass.
The average in vivo levels of systolic, diastolic, and
mean arterial blood pressures did not differ between
STZ and control groups, but the average heart rate of
the former was lower, both in vivo and in vitro (i.e., at
the experimental temperature of 32°C).
Coronary PO2 as a function of afterload
Panels A and B of Figure 2 show, respectively, the relation
between coronary venous partial pressure of oxygen (PO2)
and afterload for individual hearts (STZ and SHAM) and
for the average measurements recorded from all hearts.
Note the progressive increase of venous PO2 with meta-
bolic energy expenditure, a result consistently observed in
every heart. Diabetes did not alter the profile of the venous
PO2-afterload relation. There was no statistical difference
between the two groups in the mean values of coronary
venous PO2, particularly at the specific pressures of inter-
est: 70 mmHg and 90 mmHg (see below). Likewise, coron-
ary arterial PO2 was constant (690 mmHg) with afterload
for both STZ and SHAM cohorts (data not shown).
Aortic and coronary flow rates as functions of afterload
Each heart was electrically stimulated at 4 Hz to avoid
the confounding effects of difference in intrinsic heart
Figure 2 Coronary venous PO2 as a function of afterload. A: representative data from a STZ (filled symbols) and a SHAM (open symbols)
working heart. B: average relations. Each line (thick lines: STZ; thin lines: SHAM) represents the average of the n = 16 lines (each from a STZ heart)
or n = 17 lines (each from a SHAM heart).
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Table 1). Under working mode, and at various afterloads,
both aortic and coronary flow rates from each heart
were measured and were plotted as functions of after-
load (Figure 3A: representative data; Figure 3B: average
relations). The afterload series was terminated when the
heart neared its limit to pump, i.e., when aortic flow rate
was in the vicinity of zero. Note that the STZ hearts
were unable to pump to as high an afterload as the
SHAM hearts (105 ± 2 mmHg versus 150 ± 4 mmHg).
Work, total oxygen consumption and total efficiency as
functions of afterload
Work, total oxygen consumption (VO2) and total effi-
ciency (ɛTotal: Equation 1) were plotted as functions of
afterload, as illustrated in Figure 4, where panels A,
C and E show data from a representative heart from
both STZ and SHAM groups, and panels B, D and F
show the average relations. In all cases, the relations
between these three variables and afterload were shifted to
lower afterloads in diabetic hearts (quantified in Figure 5),
a collateral consequence of the reduced ability of theFigure 3 Aortic and coronary flow rates as functions of afterload. A: r
rates) from a STZ (filled symbols) and a SHAM (open symbols) working hea
represents the average of the n = 16 lines (each from a STZ heart) or n = 17
quantified in Tables 2 and 3.diabetic hearts to pump at high afterload. Several features
of the relations are noteworthy. (i) Consistent with data
from isolated cardiac muscle, work and ɛTotal of the iso-
lated working heart were both complex functions of after-
load, which peak at the mid-range of afterload. (ii) Neither
work nor ɛTotal were zero at the highest afterload that the
heart could pump. This is because at the highest afterload,
coronary flow rate was high despite near-zero aortic flow
(see Figure 3), and work was calculated using the sum of
aortic and coronary flow rates. (iii) Because of the previous
two features, the data allowed us to extrapolate to peak
afterload at the extreme positive value on the abscissa
where work (or ɛTotal) was zero. (iv) Lastly, the afterloads at
which the peak work was attained were not comparable to
the afterloads at which the peak ɛTotal was reached. For
example, for SHAM hearts, peak work occurred at around
110 mmHg, whereas peak ɛTotal appeared at around
80 mmHg.
Given these four interesting features of the relations, we
quantified four distinct variables (illustrated in Figure 1),
namely: (i) peak values (i.e., peak work and peak ɛTotal);
(ii) optimal afterloads (i.e., the afterloads at which peakepresentative data (circles: aortic flow rates, triangles: coronary flow
rt. B: average relations. Each line (thick lines: STZ; thin lines: SHAM)
lines (each from a SHAM heart). The variability of the relations in B is
Figure 4 Mechano-energetics variables as functions of afterload. Work (A and B), total oxygen consumption (VO2; C and D) and total
efficiency (ɛTotal; E and F) as functions of afterload for representative (A, C and E) STZ (filled circles) and SHAM (open circles) working hearts, and
for the averages of n = 16 STZ or n = 17 SHAM working hearts (B, D and F). The variability of the relations in B, D and F is quantified in Figures 5
and 6 and Tables 2 and 3.
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maximum, extrapolated, values of afterload); and (iv) values
at the peak of other variables (i.e., values of work and
total VO2 at the optimal afterloads of ɛTotal, and values
of ɛTotal and total VO2 at the optimal afterloads of work).
Quantification of the first three variables is reported in
Figure 5, whereas those for the fourth variable are shown
in Figure 6.
Peak work and peak total efficiency, optimal afterload
and peak afterload
Figure 5 compares the peak work, the peak ɛTotal, the
optimal afterload and the peak afterload for work and
for ɛTotal of the average relations shown in Figure 3B
and F. Mean peak work (A) did not differ between STZ
and SHAM hearts (P = 0.068). Mean peak ɛTotal was also
not different between STZ and SHAM hearts, 14.7 ±
0.7% versus 14.7 ± 0.5% (B). However, the mean optimal
afterload for work (C) and that for ɛTotal (D) were lower
in the STZ hearts. The mean peak afterload for work (E)
and that for ɛTotal (F) were also lower in the STZ hearts. In
addition, we also compared the mean optimal afterloadand the mean peak afterload for work with that for ɛTotal
(comparing panels C and D). For both the STZ and SHAM
hearts, the mean optimal afterload for work was greater
than that for ɛTotal, but the mean peak afterload for
work and for ɛTotal were not different (comparing panels E
and F).
Work and total oxygen consumption (VO2) at peak total
efficiency (ɛTotal), ɛTotal and total VO2 at peak work
Since the optimal afterload for work (i.e., afterload at
which work is at its peak) did not coincide with that for
ɛTotal (comparing Figure 5C and D), peak work did not
result in peak ɛTotal. Hence, we calculated the work,
along with the total VO2, at the optimal afterload for
ɛTotal. Likewise, we calculated ɛTotal and total VO2 at
peak work. Note that peak ɛTotal (Figure 5B) is the ratio
of the work values in Figure 6B to the total VO2 values
in Figure 6D. At peak ɛTotal, work did not differ between
the STZ and SHAM hearts (Figure 6B), but total VO2
was lower for the STZ hearts (Figure 6D). At peak work,
bothɛTotal and total VO2 did not differ between the two
groups (Figure 6A and C, respectively).
Figure 5 Peak work, peak total efficiency, optimal afterloads
and peak afterloads. Quantification of the average relations shown
in Figure 4B and F: peak work (A), peak total efficiency (ɛTotal; B), the
optimal afterload (AL) for work (C) and for ɛTotal (D) and the peak
afterload for work (E) and for ɛTotal (F). Values represent the mean ± SE
of n = 17 SHAM hearts and n = 16 STZ hearts. *P < 0.05, STZ versus
SHAM; +P < 0.05, optimal AF for work versus that for ɛTotal.
Figure 6 Work and total oxygen consumption (VO2) at peak
total efficiency (ɛTotal), ɛTotal and total VO2 at peak work. Further
quantification of the average relations shown in Figure 4B, D and F:
ɛTotal at peak work (A), work at peak ɛTotal (B) and total VO2 at peak
work (C) and at peak ɛTotal (D). Values represent the mean ± SE of
n = 17 SHAM hearts and n = 16 STZ hearts. *P < 0.05, STZ versus
SHAM. In B and C, the P values are 0.093 and 0.056, respectively.
Table 2 Mechano-energetics values at afterload 70 mmHg
Variable SHAM STZ
Basal rate of VO2(W kg
-1) 12.1 ± 1.07 11.5 ± 0.87
Aortic flow rate (mL g-1 min-1) 26.7 ± 1.6 26.1 ± 2.3
Coronary flow rate (mL g-1 min-1) 5.01 ± 0.29 5.74 ± 0.43
Work (J kg-1) 1.22 ± 0.07 1.24 ± 0.09
Total Vo2 (J kg
-1) 8.87 ± 0.43 9.04 ± 0.59
Total efficiency (%) 14.2 ± 0.48 14.1 ± 0.77
Mechanical efficiency (%) 21.4 ± 0.97 20.9 ± 1.26
Values are means ± SE. No statistically significant differences in mean values
between SHAM and STZ.
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We measured the basal rate of VO2 of each heart at after-
load 70 mmHg. There was no difference in the mean basal
rate of VO2 between STZ and SHAM (Table 2). At this
afterload, mean aortic flow rate and mean coronary flow
rate were not different between the two groups. Therefore,
mean work, total VO2 and total ɛTotal were also not differ-
ent between the two groups. In fact, at this afterload, the
value of these variables of the STZ hearts (when plotted as
functions of afterload) intersected those of the SHAM
hearts (Figure 4). Given the null differences in values of
these four variables between the two groups, mech-
anical efficiency at 70 mmHg (calculated using these fourvariables; Equation 2) did not differ between the STZ and
SHAM hearts.
Mechano-energetics values at afterload 90 mmHg
We chose to report the values of the mechano-energetics
variables at 90 mmHg since at this afterload the STZ hearts
were in the vicinity of their limit to pump (Figures 3
and 4). In contrast to the null results at afterload 70 mmHg
(Table 2), results at 90 mmHg are striking. As shown in
Table 3, the mean aortic flow rate of the STZ hearts was
Table 3 Mechano-energetics values at afterload 90 mmHg
Variable SHAM STZ
Aortic flow rate (mL g-1 min-1) 24.4 ± 1.5 14.2 ± 2.9*
Coronary flow rate (mL g-1 min-1) 6.05 ± 0.39 7.16 ± 0.65
Work (J kg-1) 1.48 ± 0.09 1.06 ± 0.11*
Total Vo2 (J kg
-1) 10.4 ± 0.51 10.0 ± 0.66
Total efficiency (%) 14.5 ± 0.49 10.4 ± 0.88*
Values are means ± SE. Asterisks indicates significant differences in mean
values between SHAM and STZ: *P < 0.05.
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result, in turn, was responsible for the lower value of ɛTotal
since there was no difference in the mean value of total
VO2 between the two groups.
Discussion
To our knowledge, this study presents the first compre-
hensive examination of the mechano-energetics of the
diabetic heart. We have extended the practice (common
in the literature) of reporting only a single value of myo-
cardial efficiency of the diabetic heart by reporting its
behaviour as a function of afterload. Efficiency is a com-
plex function of afterload, with values ranging from zero
to a peak (which occurs at somewhere in the mid-value
of afterload). It is thus incomplete, and misleading, to
report only a single value. We show that the efficiency-
afterload relation allows reconciliation of the conflicting
conclusions in the literature regarding the effect of dia-
betes on myocardial efficiency.
Achievement of the diabetic state
A single injection of STZ at age 6-7 weeks, clearly ren-
dered the rats diabetic 7-8 weeks later. This is demon-
strated by the 4.4-fold higher concentration of blood
glucose, the 30% lower body mass and the 23% lower
heart mass but 11% higher ratio of heart mass to body
mass (Table 1). The STZ rats developed LV hypertrophy,
as indicated by a greater average LV wall thickness rela-
tive to heart mass (Table 1), consistent with the finding
of MacDonald et al. [32]. Compared to their SHAM con-
trols, the STZ rats had a greater average lung mass per
body mass, consistent with the findings of Ofulue et al.
[33]. They also had lower average intrinsic heart rates,
as measured in vivo and in vitro (at 32°C). Bradycardia
has been a consistent finding in STZ-diabetic hearts
[19,20,22-25,32,34-36]. We obviated any influence of
bradycardia on the mechano-energetics variables by pacing
the excised hearts at 4 Hz (i.e., above the intrinsic heart
rates at 32°C).
Adequacy of oxygen supply to the isolated working-heart
The use of a crystalloid perfusate demands examination
of the adequacy of oxygen supply. We exploited theinverse relationship between temperature and oxygen
solubility–lowering the temperature of the perfusate
to 32°C, which, in turn, allowed us to reduce the pacing
frequency to 4 Hz. Thus we simultaneously increased
oxygen supply and reduced oxygen demand, both of
which manoeuvres enhance tissue oxygenation. As seen in
Figure 2, the average coronary venous PO2 was 25 mmHg
at the lowest workload examined (40 mmHg afterload).
This value can be put in perspective with reference to
Tune et al. [37] and the comprehensive review of Zong
et al. [38], who reported that resting PO2 values from the
right and left coronary veins of dogs are, respectively,
30 mmHg and 20 mmHg. It is unlikely that our observed
values indicate hypoxic conditions, given the substantial
coronary reserve revealed by the progressive increase of
venous PO2 values with afterload (consistent with the in
situ canine data of Yonekura et al. [39]). Note that the
average highest value of venous PO2 (which occurred at
the maximal afterload) was 90 mmHg for diabetic hearts
and 140 mmHg for control hearts. PO2 values above
100 mmHg exceed those associated with normoxia in vivo.
Also observed in Figure 2 is a hint of autoregulation in the
mid-range of afterloads and the probable appearance of
Gregg’s Phenomenon at higher rates of work demand.
These considerations give us confidence that the sup-
ply of oxygen to the isolated hearts was adequate and
allow us to focus on the effects of diabetes on cardiac
mechano-energetics.
Blood pressure in vivo
Given the development of bradycardia and LV hyper-
trophy in the diabetic rats, it is somewhat surprising that
no difference of either systolic or diastolic blood pressure
was observed in vivo (Table 1). Systolic blood pressure, as
well as mean arterial pressure and pulse pressure, have
been shown to be higher and to increase with the duration
of diabetes in Type 1 diabetic patients [40,41]. Elevated
blood pressure has been used as an index of arterial stiff-
ening in diabetic patients [40,41]. Arterial stiffness is
known to be higher in diabetic human tissue post-mortem
[42] as well as in the arteries [43-45] and myocytes [44] of
diabetic patients. These effects are commonly attributed
to increased fibrosis [44], deposition of advanced glycation
end-products [44,45], increased oxidative stress [45] or
low-grade inflammation [43]. The absence of any differ-
ence of blood pressure indices between STZ and SHAM
rat hearts probably reflects the difference between acute
(present study) and chronic diabetes (human patients).
Aortic flow, coronary flow and maximal afterload in vitro
The effect of STZ-induced diabetes was primarily mani-
fested on the rate of aortic flow (Figure 3B). The extent
of decrease of the aortic flow with increasing afterload
was greater for the STZ hearts, resulting in negligible
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contrast, the SHAM hearts did not achieve zero aortic flow
until challenged by an average afterload of 150 mmHg.
This demonstrates that the LV of the STZ heart fails to
generate as high a pressure as the normal heart in vitro.
This finding is consistent with the reduced peak de-
veloped LV pressure of aortic-occluded diabetic hearts
[25] and the reduced peak LV systolic pressure reported by
others [4,9,21-25].
However, there are also studies showing no effect
of STZ on LV systolic pressure [1,2,19,20]. Nevertheless,
it is striking that the clear difference in maximum LV
pressure development between STZ and SHAM hearts
in vitro (Figure 3) stands in contrast to the absence of
any differences among systolic, mean or diastolic pres-
sures measured in vivo (Table 1). The literature on these
discrepant results once again lacks consensus. Whereas
it is not uncommon to read that STZ-diabetic cardio-
myopathy in rats lowers mean arterial pressure signifi-
cantly [46-49], most groups have reported no difference
[19,20,23,34,35,49-51], while some have even reported
higher mean values [52,53]. Clearly, any observed re-
sponse of either mean arterial pressure or LV pressure
can be accommodated. In fact, both Radovits et al. [23]
and Cheng et al. [35] reported lower in vivo LV systolic
pressure with no change of mean arterial pressure in the
STZ-diabetic rats. Our results, showing reduced maximal
afterload (Figure 3) and similar mean arterial pressure
(Table 1), are in accord.
At the maximum afterload (when the aortic flow rate
is near zero), the coronary flow rate is maximal. STZ-
treatment has negligible effect on the maximum rate of
coronary flow (8-10 mL min-1 g-1), in accord with the
finding of Joffe et al. [24] who showed no effect of STZ
on coronary perfusion pressure of the in vitro heart.
This suggests that autoregulation of the heart, which
is responsible for the relatively constant coronary flow
within an afterload region between around 60 mmHg to
100 mmHg (Figure 3), is unaffected by STZ treatment. At
the maximum afterload, since the coronary flow rate is
maximal, the derived work output of the heart is small but
non-zero (since aortic flow rate is near zero; Figure 4A). In
consequence, the calculated total efficiency (Equation 1)
is a small value (Figure 4E). This has prompted us to
extrapolate the curves fitted to the work-afterload and
efficiency-afterload data to predict the peak value of after-
load. These extrapolated values approximate the systolic
pressure of an isovolumic contraction. Since the predicted
maximum afterload of the STZ hearts is lower (105 mmHg
versus 150 mmHg; Figure 3), the predicted peak afterload
(or isovolumic pressure) of the STZ hearts is consistently
lower (114 mmHg versus 169 mmHg; Figure 5E and F).
Reassuringly, the predicted peak afterload does not differ
in value whether it is extrapolated from the work-afterloadcurve (Figure 5E) or from the efficiency-afterload curve
(Figure 5F).
Peak values of work and of total efficiency in vitro
These two peak values occur at neither the maximum
afterload nor the predicted peak afterload. Instead, they
occur at their optimal afterloads, as shown in Figure 4 and
quantified in Figure 5C and D. Given that STZ reduces the
maximum afterload and the predicted peak afterload, the
optimal afterload is necessarily reduced. Despite this effect,
the peak value of total efficiency (14-15%) is unaffected by
STZ (Figures 4F and 5B). These values of total efficiency
fall within the range of the literature values reported for
the normal rat heart [54].
Note that the average efficiency-afterload curve of the
STZ hearts intersects that of the SHAM hearts at an
afterload of approximately 70 mmHg (Figure 4F). At this
afterload, diabetes has negligible effects (Table 2) on ei-
ther aortic or coronary flow rates, work output, total oxy-
gen consumption, total efficiency, or basal rate of oxygen
consumption. Correction for the basal rate of oxygen
consumption (Equation 2) reveals that the mechanical
efficiency, at least at afterload 70 mmHg, is unaffected
by STZ.
Optimisation of the heart for mechano-energetics
As is also evident in Figures 4 and 5, the optimal after-
load for peak work is different from that for peak total
efficiency. The former occurs at a greater value of after-
load than the latter, and this is independent of diabetic
status. This result, in the intact whole-heart, is consist-
ent with the results obtained in isolated one-dimensional
cardiac preparations, such as papillary muscles [10-16]
and trabeculae carneae [17,18].
We can calculate the value of work at which total effi-
ciency is at its peak, and vice versa (Figure 5). But since
the optimal afterload for peak work is greater than that
for peak total efficiency, this has raised a question as to
whether the STZ and SHAM hearts, in vivo, operate at
some high afterload (90 mmHg, for example) or at the
afterload that optimises either work or total efficiency. If
they operate at their optimal afterloads for peak work,
then they have the same total efficiency. If they operate
at their optimal afterloads for peak total efficiency, then
they again have the same total efficiency. But if they both
operate at high afterload, then the STZ heart would have a
relatively lower total efficiency (Table 3). The literature on
the concept of ‘optimisation’ (the matching of either peak
work or peak efficiency to arterial load) is inconclusive
[55-62], but, as pointed out by Elzinga and Westerhof [63]
and by de Tombe et al. [64], it scarcely matters. The after-
loads at which these two maxima occur do not differ
greatly, i.e., both the work and efficiency are greater
than 90% of their respective optima. Our results, for both
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the literature, we think that the heart operates within
the range of optimal afterloads for peak work and for
peak total efficiency. Our results, on isolated hearts,
show that the STZ-diabetic heart operates optimally
at afterloads 60-70 mmHg, lower than those for the healthy
heart (80-100 mmHg). Despite operating at a lower after-
load, the STZ-diabetic heart pumps as efficiently as the
healthy heart (14.7%). We thus infer that the diabetic heart,
under normal conditions, pumps as efficiently as the
healthy heart, but if it is challenged with any intervention
that requires it to pump at high afterloads, then its effi-
ciency will be lower than that of the healthy heart.
Reporting a single value of efficiency
Because of the complex dependencies of efficiency on
afterload, it is unwise to perform experiments at only a
single afterload, and to report a single value of efficiency,
unless one has a priori knowledge of the relation be-
tween efficiency and afterload. If we had performed only
a single experiment at a high afterload (for example,
90 mmHg), to examine the effect of diabetes, then we
would have reported that the diabetic heart has a lower
value of efficiency. We consider it necessary that experi-
ments be performed at a range of afterloads since, by
doing so, the optimal afterload at which the heart oper-
ates can be ascertained. If only a single value of efficiency
is reported, then it is essential to report the afterload at
which that value was obtained. In fact, this was done by
Penpargkul et al. [9] who reported that they had per-
formed all measurements at a fixed afterload of approxi-
mately 60 mmHg. It was their serendipitous choice of
this value that allowed them to find no effect of diabetes
upon myocardial work output, oxygen consumption or
total efficiency – a result in accord with our findings re-
ported in Figure 4.
Conclusions
Streptozotocin-induced diabetes limits the ability of the
heart to pump at high afterloads. A collateral consequence
is a left-shift of the myocardial efficiency-afterload curve,
resulting in reduced efficiency of the diabetic heart at high
afterloads. However, the peak efficiency (which occurs at
the mid-range of the efficiency-afterload curve) of the heart
is unaffected by diabetes. These findings reconcile the con-
flicting reports in the literature regarding the effect of dia-
betes on myocardial efficiency.
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